Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118079052 | 11807905 | 2 | F | 2013 | 20160706 | 20151207 | 20160714 | EXP | US-SA-2015SA199061 | AVENTIS | 69.00 | YR | E | F | Y | 72.50000 | KG | 20160714 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118079052 | 11807905 | 1 | PS | LANTUS SOLOSTAR | INSULIN GLARGINE | 1 | Unknown | DOSE:50 UNIT(S) | 5F1883A | 21081 | INJECTION | QD | |||||||
| 118079052 | 11807905 | 2 | C | SOLOSTAR | DEVICE | 1 | 0 | QD | |||||||||||
| 118079052 | 11807905 | 3 | C | LOSARTAN. | LOSARTAN | 1 | DOSE:1 UNIT(S) | 0 | |||||||||||
| 118079052 | 11807905 | 4 | C | SIMVASTATIN. | SIMVASTATIN | 1 | DOSE:1 UNIT(S) | 0 | |||||||||||
| 118079052 | 11807905 | 5 | C | NOVOLOG | INSULIN ASPART | 1 | DOSE:3 UNIT(S) | 0 | QD | ||||||||||
| 118079052 | 11807905 | 6 | C | ZYRTEC | CETIRIZINE HYDROCHLORIDE | 1 | DOSE:1 UNIT(S) | 0 | |||||||||||
| 118079052 | 11807905 | 7 | C | FLUTICASONE | FLUTICASONEFLUTICASONE PROPIONATE | 1 | DOSE:2 UNIT(S) | 0 | QD | ||||||||||
| 118079052 | 11807905 | 8 | C | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | DOSE:1 UNIT(S) | 0 | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 118079052 | 11807905 | 1 | Type 2 diabetes mellitus |
| 118079052 | 11807905 | 2 | Type 2 diabetes mellitus |
| 118079052 | 11807905 | 3 | Blood pressure measurement |
| 118079052 | 11807905 | 4 | Blood cholesterol |
| 118079052 | 11807905 | 5 | Diabetes mellitus |
| 118079052 | 11807905 | 6 | Hypersensitivity |
| 118079052 | 11807905 | 7 | Sinus disorder |
| 118079052 | 11807905 | 8 | Gastrooesophageal reflux disease |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 118079052 | 11807905 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 118079052 | 11807905 | Macular oedema | |
| 118079052 | 11807905 | Retinopathy | |
| 118079052 | 11807905 | Visual impairment |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 118079052 | 11807905 | 1 | 1997 | 0 | ||
| 118079052 | 11807905 | 2 | 1997 | 0 |